Medical device therapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a device called TheraBionic P1 that sends a very low level of electromagnetic energy through your body. It is for people with triple-negative breast cancer that has continued to grow despite at least two earlier treatments. The goal is to see if this gentle, non-invasive approach can help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that is triple-negative, meaning it tested negative for estrogen, progesterone, and HER2 receptors.
- Your cancer must have spread to other parts of the body or be measurable on a scan, and you must have already tried at least two standard treatments.
- You must be a woman aged 22 or older.
- You must be well enough to care for yourself and have a life expectancy of at least three months.
- You cannot be pregnant or breastfeeding, and you must agree to use birth control if there is any chance of pregnancy.
- You cannot have untreated brain metastases, active mouth sores or infections, or a severe allergy to nickel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.